Rutgers University is a clinical trial site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s phase 3 clinical research study to evaluate the safety and efficacy of Janssen’s COVID-19 vaccine candidate. Rutgers will enroll as many as 2,000 participants from the university community and throughout New Jersey. Study participants who meet the eligibility requirements for the study will be randomly selected to receive a single dose of the potential vaccine or a placebo. Researchers will track whether those who are vaccinated have lower rates of infection with moderate to severe symptoms than those who were unvaccinated. To read the full story.